IBRX.US Immunitybio Inc

Healthcare Biotechnology USA Stocks
6.02 USD
Close of Nov 15, 2026
1.95 12.43
Market cap
USD 6.40B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IBRX.US undervalued?

Graham number

The Graham number of Immunitybio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immunitybio Inc fundamental analysis

No fundamental analysis for Immunitybio Inc yet.

Immunitybio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immunitybio Inc

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic ag…

Full company profile